Anke Bio: First Phase I Clinical Trial for Global First CD7 CAR-T Pediatric Indication Launched
Anke Bio's subsidiary, Boshengji Medicine, has initiated a Phase 1 clinical trial for its CD7 CAR-T therapy in pediatric patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma. This marks a significant advancement for cell therapy in treating aggressive childhood blood cancers, particularly for children who have exhausted conventional treatment options. The trial, held at the Institute of Hematology, Chinese Academy of Medical Sciences, signifies a breakthrough for China-developed cell therapies in pediatric hematology. AI
IMPACT This trial represents a significant step forward in cell therapy for pediatric blood cancers, potentially offering new hope for patients with limited treatment options.